Nowarat Songsiridej, MD
Rheumatology · Bismarck, NDNPI 1346321429
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $515 of the $665 with a category attached, or 77.4%. 9 manufacturers reported payments, led by Amgen at 26.0% of the total. Reporting peaked in 2019 at $249 and has fallen 80.7% since, to $48 in 2025.
Across 14 payments — averaging $47.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$173
- Biogen$150
- AstraZeneca$100
- AbbVie$98
- UCB, Inc.$50
- E.r. Squibb & Sons, L.L.C.$48
- plus $45 from 3 others
What the payments were for
- Consulting fees$15023%
- Food & beverage$51577%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 6 | $173 |
| Biogen | 1 | $150 |
| AstraZeneca | 1 | $100 |
| AbbVie | 1 | $98 |
| UCB, Inc. | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 1 | $48 |
| Pharming Healthcare, Inc. | 1 | $17 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few rheumatology providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Orencia ClickjectAbatacept | 11 | $68,693 |
| Hydroxychloroquine Sulfate | 270 | $15,780 |
| MethotrexateMethotrexate Sodium | 427 | $12,424 |
| Leflunomide | 77 | $5,653 |
| Sulfasalazine | 42 | $1,859 |
| Celecoxib | 34 | $1,535 |
| Prednisone | 216 | $1,156 |
| Mycophenolate Mofetil | 18 | $1,127 |
| Colchicine | 23 | $801 |
| Doxycycline Hyclate | 49 | $582 |
| Diclofenac Sodium | 19 | $400 |
| Sulindac | 12 | $361 |
| Azithromycin | 19 | $343 |
| Nabumetone | 27 | $329 |
| Fluconazole | 14 | $251 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Bismarck
- Christian DequetBismarck$8K
- Jonathan HiltsBismarck$2K
- Yuri NakasatoFargo$6K
- Esperanza ArgenzianoGrand Forks$1K
- Mosaab MohamedenFargo$793
- Viktorija OverieneFargo$636
- Erdal DiriMinot$291
- Meghan ScheibeFargo$149
- Lorna CampbellFargo$45
- Mahfooz PeshimamFargo$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.